Literature DB >> 16721571

99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.

A Hubalewska-Dydejczyk1, K Fröss-Baron, R Mikołajczak, H R Maecke, B Huszno, D Pach, A Sowa-Staszczak, B Janota, P Szybiński, J Kulig.   

Abstract

PURPOSE: At all stages of the disease, serious difficulties are encountered in the imaging diagnosis of carcinoids. Somatostatin receptor scintigraphy (SRS) holds great promise for detecting primary tumours and metastases. 99mTc-EDDA/HYNIC-octreotate should significantly improve the diagnosis of carcinoids in comparison with 111In-Octreoscan owing to the better affinity for SSR2 and the higher count rate. The aim of this study was to assess the diagnostic efficiency of 99mTc-EDDA/HYNIC-octreotate scintigraphy in the detection and staging of carcinoid tumours.
METHODS: The study population comprised 75 patients (age 48.5+/-15.5 years): 46 with histological confirmation of carcinoid and 29 with suspected disease. 99mTc-EDDA/HYNIC-octreotate (740 MBq) SRS and CT were performed in all patients. Fifteen patients were examined with 111In-Octreoscan.
RESULTS: High-quality 99mTc-EDDA/HYNIC-octreotate images were obtained in all cases, with maximum tumour tracer accumulation 4 h p.i. The mean target/non-target ratios for whole body (WB) and SPECT scans were, respectively, as follows: primary lesions: 4.5 and 10.2; metastases: liver, 3.1 and 12.3; abdominal focal lesions, 2.7 and 5.8; lung, 2.7 and 8.3; mediastinum, 3.4 and 7.6; bones, 6.8 and 19.0. 99mTc-EDDA/HYNIC-octreotate WB scans revealed more metastases than 111In-Octreoscan, with better individual separation. 99mTc-EDDA/HYNIC-octreotate SRS revealed new metastatic lesions in seven patients with confirmed carcinoid, and in four with dissemination the primary focus was found. Five patients qualified for radioguided surgery and 11 were referred to 90Y-DOTA-TATE therapy. The sensitivity of SRS in comparison with CT was higher for primary lesions and liver and abdominal lymph node metastases. In the subgroup of patients with suspected neuroendocrine tumours, two duodenal carcinoids, one thymic carcinoid and one ileal carcinoid were found.
CONCLUSION: 99mTc-EDDA/HYNIC-octreotate, with high imaging quality, is an excellent alternative to 111In-Octreoscan for staging of carcinoids, and it seems to be the method of choice for detection of the primary focus in patients with metastases from an unknown primary tumour.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721571     DOI: 10.1007/s00259-006-0113-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

1.  Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence.

Authors:  C Decristoforo; S J Mather
Journal:  Eur J Nucl Med       Date:  1999-08

2.  Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector.

Authors:  S A Benjegård; E Forssell-Aronsson; B Wängberg; J Skånberg; O Nilsson; H Ahlman
Journal:  Eur J Nucl Med       Date:  2001-10

3.  Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection.

Authors:  J W Babich; H Solomon; M C Pike; D Kroon; W Graham; M J Abrams; R G Tompkins; R H Rubin; A J Fischman
Journal:  J Nucl Med       Date:  1993-11       Impact factor: 10.057

Review 4.  Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.

Authors:  Kjell Oberg; Barbro Eriksson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2005-06       Impact factor: 4.690

5.  99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.

Authors:  C Decristoforo; S J Mather; W Cholewinski; E Donnemiller; G Riccabona; R Moncayo
Journal:  Eur J Nucl Med       Date:  2000-09

Review 6.  Metastatic carcinoid tumors: a clinical review.

Authors:  Johanna M Zuetenhorst; Babs G Taal
Journal:  Oncologist       Date:  2005-02

7.  99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study.

Authors:  Clemens Decristoforo; Theodosia Maina; Berthold Nock; Michael Gabriel; Paul Cordopatis; Roy Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-04       Impact factor: 9.236

8.  Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?

Authors:  H Amthauer; J Ruf; M Böhmig; E Lopez-Hänninen; T Rohlfing; K-D Wernecke; U Plöckinger; M Gutberlet; A-J Lemke; T Steinmüller; B Wiedenmann; R Felix
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-03       Impact factor: 9.236

Review 9.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

10.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.

Authors:  A Chiti; S Fanti; G Savelli; A Romeo; B Bellanova; M Rodari; B J van Graafeiland; N Monetti; E Bombardieri
Journal:  Eur J Nucl Med       Date:  1998-10
View more
  18 in total

1.  Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.

Authors:  L de la Cueva; P Lloro; M J Sangrós; L López Vélez; P Navarro; L Sarria; S Álvarez; D Abós
Journal:  Clin Transl Oncol       Date:  2017-01-31       Impact factor: 3.405

Review 2.  Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

Authors:  Sander M Bison; Mark W Konijnenberg; Marleen Melis; Stefan E Pool; Monique R Bernsen; Jaap J M Teunissen; Dik J Kwekkeboom; Marion de Jong
Journal:  Clin Transl Imaging       Date:  2014-03-05

Review 3.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 4.  Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

Authors:  Martijn van Essen; Anders Sundin; Eric P Krenning; Dik J Kwekkeboom
Journal:  Nat Rev Endocrinol       Date:  2013-12-10       Impact factor: 43.330

5.  Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract.

Authors:  A Hubalewska-Dydejczyk; J Kulig; P Szybinski; R Mikolajczak; D Pach; A Sowa-Staszczak; K Fröss-Baron; B Huszno
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-07-25       Impact factor: 9.236

6.  Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.

Authors:  Rafał Czepczyński; Maria Gemma Parisella; Jerzy Kosowicz; Renata Mikołajczak; Katarzyna Ziemnicka; Maria Gryczyńska; Jerzy Sowiński; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-26       Impact factor: 9.236

7.  SPECT/CT with radiolabeled somatostatin analogues in the evaluation of systemic granulomatous infections.

Authors:  Paulo Henrique Silva Monteiro; Thiago Ferreira de Souza; Maria Luiza Moretti; Mariangela Ribeiro Resende; Jair Mengatti; Mariana da Cunha Lopes de Lima; Allan Oliveira Santos; Celso Darío Ramos
Journal:  Radiol Bras       Date:  2017 Nov-Dec

8.  Radiolabeled peptides: valuable tools for the detection and treatment of cancer.

Authors:  M Fani; H R Maecke; S M Okarvi
Journal:  Theranostics       Date:  2012-05-16       Impact factor: 11.556

Review 9.  Imaging of anterior mediastinal masses.

Authors:  Leslie E Quint
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

Review 10.  Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice.

Authors:  Edmond Rust; Fabrice Hubele; Ettore Marzano; Bernard Goichot; Patrick Pessaux; Jean-Emmanuel Kurtz; Alessio Imperiale
Journal:  Cancer Imaging       Date:  2012-05-21       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.